Sentence examples for combinations for future from inspiring English sources

Using these rules, we prioritize ∼105 human TSG-drug combinations for future follow-up.

Understanding the mechanisms by which EGFR inhibition modulates repair of DNA damage will inform design of optimal combinations for future studies and is critical to maximise benefits in the clinical setting.

Understanding the mechanistic basis for interactions of these novel targeted agents with DNA-interactive drugs will inform design of optimal combinations for future studies and is critical to maximize benefit in the clinic.

This information should guide the choice of comparators, including their dose and combinations, for future large trials.

In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.

The proposed scaffold model can be suggested for delivering of cells and other growth factors such as vascular endothelial growth factor (VEGF), alone or in combination, for future investigations.

The assessment of the value of controlling these factors, and their combination, for future developments requires support of biological testing in appropriate mechanistic models, but also imperatively demand confirmation in therapeutically relevant in vivo models for biodistribution, efficacy, and lack of off-target effects.

The toxicity profile of the combination was similar to what would be expected with docetaxel alone and a dose for the combination for future studies has been identified.

In this study quantitative estimates of radiation distribution and RIT in the xenograft model provided more insight into selecting the most suitable combination for future RIT.

We aim to analyse the results of all the SCOTROC 2 trials together (including docetaxel and paclitaxel-based schedules) in order to evaluate the optimal sequence and drug combination for future Phase III testing of a sequential approach to standard, concurrent two-drug chemotherapy administration.

Most importantly, these gene candidates display methylation frequencies ranging from 50% to 83% in DCIS and up to 93% in stage I breast cancer, depending on the target gene, and these candidates hold great promise, alone or in combination, for future diagnostic applications.